Intellipharmaceutics International Inc. (I)(製薬・医療分野):企業M&A動向

◆英語タイトル:Intellipharmaceutics International Inc. (I) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH140544D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月25日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary

Intellipharmaceutics International Inc. (Intellipharmaceutics) is a pharmaceutical company. The company holds expertise in research, development and manufacture of novel and generic targeted-release and controlled-release oral solid dosage drugs. Its product portfolio includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR and Generic Pristiq. Intellipharmaceutics offers products in the areas of neurology, gastrointestinal tract, cardiovascular, diabetes and pain. The company’s technology portfolio includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliShuttle, and IntelliPellets among others. It has partnership with Par Pharmaceutical, Inc. The company was formerly known as Intellipharmaceutics Ltd. Intellipharmaceutics is headquartered in Toronto, Ontario, Canada.

Intellipharmaceutics International Inc. (I) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 7
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 8
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deal Details 9
Partnerships 9
Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 9
Merger 10
Vasogen Merges With IntelliPharmaCeutics 10
Licensing Agreements 12
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Equity Offering 13
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 13
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 14
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 15
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 16
Intellipharmaceutics International Completes Private Placement Of Units For US$12 Million 18
Debt Offering 20
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 20
Intellipharmaceutics International Inc. – Key Competitors 21
Key Employees 22
Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
Intellipharmaceutics International Inc., Deals By Therapy Area, 2009 to YTD 2015 7
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 8
Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 9
Vasogen Merges With IntelliPharmaCeutics 10
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 13
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 14
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 15
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 16
Intellipharmaceutics International Completes Private Placement Of Units For US$12 Million 18
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 20
Intellipharmaceutics International Inc., Key Competitors 21
Intellipharmaceutics International Inc., Key Employees 22

List of Figures
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
Intellipharmaceutics International Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 7

★調査レポート[Intellipharmaceutics International Inc. (I)(製薬・医療分野):企業M&A動向] (コード:GDPH140544D)販売に関する免責事項を必ずご確認ください。
★調査レポート[Intellipharmaceutics International Inc. (I)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆